Sangamo Therapeutics, Inc. (SGMO)
OTCMKTS · Delayed Price · Currency is USD
0.1851
+0.010785 (6.19%)
At close: May 26, 2026
Sangamo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34.56 | 39.55 | 57.8 | 176.23 | 111.3 | 110.7 | |
Revenue Growth (YoY) | -45.80% | -31.57% | -67.20% | 58.34% | 0.54% | -6.34% |
Cost of Revenue | 112.67 | 112.67 | 111.32 | 230.46 | 249.9 | 230.82 |
Gross Profit | -78.11 | -73.12 | -53.52 | -54.23 | -138.6 | -120.12 |
Selling, General & Admin | 31.65 | 34.89 | 44.73 | 60.07 | 62.68 | 63.22 |
Operating Expenses | 32.21 | 34.89 | 44.73 | 60.07 | 62.68 | 63.22 |
Operating Income | -110.32 | -108 | -98.25 | -114.29 | -201.28 | -183.34 |
Interest & Investment Income | 1.29 | 1.3 | 1.51 | 8.25 | 6.43 | 5.35 |
Currency Exchange Gain (Loss) | -3.7 | -3.7 | 1.6 | 2.85 | - | - |
Other Non Operating Income (Expenses) | 1.95 | 0.14 | 2.75 | - | - | - |
EBT Excluding Unusual Items | -110.78 | -110.27 | -92.39 | -103.19 | -194.85 | -177.99 |
Merger & Restructuring Charges | - | - | -0.2 | -4.7 | - | - |
Impairment of Goodwill | - | - | - | -38.14 | - | - |
Asset Writedown | -13.24 | -13.24 | -5.52 | -116.88 | - | - |
Other Unusual Items | - | - | - | - | 3 | - |
Pretax Income | -124.02 | -123.5 | -98.11 | -262.9 | -191.85 | -177.99 |
Income Tax Expense | -0.69 | -0.57 | -0.17 | -5.07 | 0.43 | 0.31 |
Earnings From Continuing Operations | -123.33 | -122.93 | -97.94 | -257.83 | -192.28 | -178.3 |
Minority Interest in Earnings | - | - | - | - | - | 0.01 |
Net Income | -123.33 | -122.93 | -97.94 | -257.83 | -192.28 | -178.29 |
Net Income to Common | -123.33 | -122.93 | -97.94 | -257.83 | -192.28 | -178.29 |
Shares Outstanding (Basic) | 323 | 280 | 202 | 174 | 154 | 145 |
Shares Outstanding (Diluted) | 323 | 280 | 202 | 174 | 154 | 145 |
Shares Change (YoY) | 52.37% | 38.92% | 15.62% | 13.02% | 6.76% | 7.53% |
EPS (Basic) | -0.38 | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
EPS (Diluted) | -0.38 | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
Free Cash Flow | -90.46 | -97.31 | -67.41 | -246 | -243.8 | -256.53 |
Free Cash Flow Per Share | -0.28 | -0.35 | -0.33 | -1.41 | -1.58 | -1.77 |
Gross Margin | -226.04% | -184.86% | -92.60% | -30.77% | -124.53% | -108.51% |
Operating Margin | -319.25% | -273.07% | -169.98% | -64.85% | -180.85% | -165.62% |
Profit Margin | -356.89% | -310.81% | -169.45% | -146.30% | -172.76% | -161.05% |
Free Cash Flow Margin | -261.76% | -246.03% | -116.62% | -139.59% | -219.05% | -231.73% |
EBITDA | -106.66 | -104.04 | -93.14 | -99.23 | -189.17 | -173.9 |
EBITDA Margin | - | -263.05% | -161.14% | -56.31% | -169.97% | -157.09% |
D&A For EBITDA | 3.66 | 3.96 | 5.11 | 15.07 | 12.11 | 9.44 |
EBIT | -110.32 | -108 | -98.25 | -114.29 | -201.28 | -183.34 |
EBIT Margin | - | -273.07% | -169.98% | -64.85% | -180.85% | -165.61% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.